More on MBCOF
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.12 |
|
|||
| Open | $0.13 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $0.13 | ||||
| Day Low | $0.12 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 38,000 | ||||
- Marvel Biosciences receives Australian patent allowance for MB-204
- Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
- Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
- Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
- Marvel Biosciences secures funding for autism drug trial from 5 Horizons
- Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
- Marvel Biosciences secures funding for autism drug trial
- Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
- Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
- Marvel Biosciences receives US patent for autism drug candidate MB-204
Entities mentioned with MBCOF
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Show More...
